Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Social Science & Medicine (1982)|October 9, 2002
"Come back when you're dying:" the commodification of AIDS among California's urban poorJohanna Crane, Kathleen Quirk, Ariane van der StratenNaunyn-Schmiedeberg'S Archives of Pharmacology|August 24, 2004
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptorsAntony R Knight, Anil Misra, Kathleen Quirk, et al.Dimensions of Critical Care Nursing : DCCN|April 1, 2026
Variables Associated With Central Venous Catheter Occlusions in 2 Pediatric ICUs With Differing Maintenance ProtocolsKathleen Quirk, Laura Berbert, Alexandra Cole, et al.Journal of Perinatology : Official Journal of the California Perinatal Association|April 11, 2025
Increasing length board use in a neonatal intensive care unit: a quality improvement initiativeYvette Penner, Sabah Sabir, Kathleen Quirk, et al.Journal of Medicinal Chemistry|April 19, 2002
3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channelsIan Collins, Christopher Moyes, William B Davey, et al.Bioorganic & Medicinal Chemistry Letters|November 1, 2005
Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonistsDavid R Adams, Jonathan M Bentley, Karen R Benwell, et al.Journal of Medicinal Chemistry|November 11, 2005
7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal modelsRobert W Carling, Andrew Madin, Alec Guiblin, et al.Pageof 1